Tom Shepherd Consulting
The Business of Life Sciences
“No matter how solid the science, the technology or the product, building real value without the best business strategy is unlikely"
Profile
Career
Expertise Offered
Previous Achievements
Senior management profile
Tom Shepherd has over 30 years of international experience, holding senior management or CEO positions on three continents, with a track record of accomplishment.
Since launching as an independent consultant at the end of 2014, Tom works with clients in the USA, UK, Switzerland and France as advisor, board director or part-time CEO.
Board level experience
- Create and deliver the global strategy
- Lead and motivate teams
- Develop partnerships
- Raise capital from investors
- Manage international mergers / acquisitions
- Commercialise science
Adding strategic value
The principle objective of a life sciences company is to realise the optimum value from its science, technology or products. Board directors have a key role in overseeing the definition and implementation of the strategy that links the science and technology to the market.
Expertise
- Definition of the strategy linking science, business and financial objectives
- Oversight of strategy implementation
- Mentoring the management team
- Fund raising from investors
- International introductions - fluent in English and French
- Business development, mergers and acquisitions
- Project and investment due diligence
Strategy:
- Defined the therapeutic strategy for an antiviral product resulting in a major out-licensing agreement
- Redefined core strategy in cell therapy resulting in a significant investment
- Moved technology development company into profit with a focused services strategy
- Defined and implemented new partnering strategy in antibody field resulting in major transaction with a leading multinational
Fund raising and deals:
- Successful IPO in Australian market
- Completed several rounds of fund raising from established VC funds
- Out-licensed 10 major products and technologies, including an up-front of $130M
- Collaboration agreements signed with Amgen, Pfizer, GSK, Schering-Plough, Merck, Novo-Nordisk, Sanofi, AstraZeneca, Novartis, Astellas, Janssen
- Acquired US therapeutics company and started first clinical trials
Contact:
Tom Shepherd, Ph.D.
